- 現金殖利率: 4.54%、總殖利率: 4.54%、5年平均現金配發率: 39.31%
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
| EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 (5) | 6.03 | 37.05 | 2.00 | 0.0 | 0.00 | 0 | 33.17 | -27.03 | 0.00 | 0 | 33.17 | -27.03 |
| 2024 (4) | 4.40 | 94.69 | 2.00 | 0 | 0.00 | 0 | 45.45 | 0 | 0.00 | 0 | 45.45 | 0 |
| 2023 (3) | 2.26 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 26Q1 (8) | 1.95 | -38.49 | 33.56 | 2.45 | -32.69 | 22.5 | 1.95 | -67.72 | 33.56 |
| 25Q4 (7) | 3.17 | 832.35 | 50.24 | 3.64 | 372.73 | 40.54 | 6.04 | 110.45 | 37.27 |
| 25Q3 (6) | 0.34 | -67.92 | 78.95 | 0.77 | -48.67 | 13.24 | 2.87 | 13.89 | 25.33 |
| 25Q2 (5) | 1.06 | -27.4 | 125.53 | 1.50 | -25.0 | 50.0 | 2.52 | 72.6 | 20.0 |
| 25Q1 (4) | 1.46 | -30.81 | 0.0 | 2.00 | -22.78 | 0.0 | 1.46 | -66.82 | 0.0 |
| 24Q4 (3) | 2.11 | 1010.53 | 0.0 | 2.59 | 280.88 | 0.0 | 4.40 | 92.14 | 0.0 |
| 24Q3 (2) | 0.19 | -59.57 | 0.0 | 0.68 | -32.0 | 0.0 | 2.29 | 9.05 | 0.0 |
| 24Q2 (1) | 0.47 | 0.0 | 0.0 | 1.00 | 0.0 | 0.0 | 2.10 | 0.0 | 0.0 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/6 | 0.89 | -0.1 | 12.05 | 5.38 | 2.97 | 2.67 | N/A | - | ||
| 2026/5 | 0.9 | 1.42 | -2.87 | 4.48 | 1.33 | 2.77 | N/A | - | ||
| 2026/4 | 0.88 | -11.03 | 0.78 | 3.59 | 2.44 | 2.65 | N/A | - | ||
| 2026/3 | 0.99 | 27.68 | -0.44 | 2.7 | 3.0 | 2.7 | 0.0 | - | ||
| 2026/2 | 0.78 | -16.53 | 2.16 | 1.71 | 5.11 | 2.95 | 0.0 | - | ||
| 2026/1 | 0.93 | -24.66 | 7.71 | 0.93 | 7.71 | 3.16 | 0.0 | - | ||
| 2025/12 | 1.24 | 24.24 | 0.54 | 10.81 | 1.4 | 3.16 | 0.0 | - | ||
| 2025/11 | 1.0 | 7.5 | 6.46 | 9.58 | 1.51 | 2.72 | 0.0 | - | ||
| 2025/10 | 0.93 | 15.93 | 6.57 | 8.58 | 0.97 | 2.59 | 0.0 | - | ||
| 2025/9 | 0.8 | -7.22 | 2.37 | 7.66 | 0.33 | 2.44 | 0.0 | - | ||
| 2025/8 | 0.86 | 10.88 | 3.74 | 6.86 | 0.1 | 2.44 | 0.0 | - | ||
| 2025/7 | 0.78 | -2.79 | 1.31 | 6.0 | -0.39 | 2.5 | 0.0 | - | ||
| 2025/6 | 0.8 | -13.41 | -5.28 | 5.22 | -0.64 | 2.6 | 0.0 | - | ||
| 2025/5 | 0.92 | 5.24 | 13.66 | 4.42 | 0.24 | 2.8 | 0.0 | - | ||
| 2025/4 | 0.88 | -12.12 | 3.72 | 3.5 | -2.78 | 2.63 | 0.0 | - | ||
| 2025/3 | 1.0 | 31.01 | -5.25 | 2.62 | -4.78 | 2.62 | 0.0 | - | ||
| 2025/2 | 0.76 | -12.0 | -4.57 | 1.63 | -4.49 | 2.86 | 0.0 | - | ||
| 2025/1 | 0.86 | -29.67 | -4.41 | 0.86 | -4.41 | 3.03 | 0.0 | - | ||
| 2024/12 | 1.23 | 31.55 | 1.87 | 10.66 | 9.0 | 3.03 | 0.0 | - | ||
| 2024/11 | 0.93 | 7.62 | 0.96 | 9.43 | 10.0 | 2.58 | 0.0 | - | ||
| 2024/10 | 0.87 | 11.36 | -1.43 | 8.5 | 11.09 | 2.48 | 0.0 | - | ||
| 2024/9 | 0.78 | -5.98 | -0.85 | 7.63 | 12.73 | 2.38 | 0.0 | - | ||
| 2024/8 | 0.83 | 8.27 | -0.39 | 6.85 | 14.51 | 2.44 | 0.0 | - | ||
| 2024/7 | 0.77 | -9.11 | -4.9 | 6.02 | 16.93 | 2.42 | 0.0 | - | ||
| 2024/6 | 0.84 | 3.9 | 7.68 | 5.25 | 20.98 | 2.5 | 0.0 | - | ||
| 2024/5 | 0.81 | -3.96 | 3.29 | 4.41 | 23.9 | 2.71 | 0.0 | - | ||
| 2024/4 | 0.84 | -19.72 | 3.83 | 3.6 | 29.73 | 2.7 | 0.0 | - | ||
| 2024/3 | 1.05 | 31.94 | 40.33 | 2.76 | 40.48 | 2.76 | N/A | - | ||
| 2024/2 | 0.8 | -11.85 | 27.13 | 1.7 | 40.58 | 2.91 | N/A | - | ||
| 2024/1 | 0.9 | -25.04 | 55.03 | 0.9 | 55.03 | 3.04 | N/A | 因疫情解封致營收成長 | ||
| 2023/12 | 1.21 | 30.37 | 66.17 | 9.78 | 79.09 | 3.01 | N/A | 因疫情解封致營收成長 | ||
| 2023/11 | 0.93 | 5.06 | 91.13 | 8.58 | 81.07 | 2.59 | N/A | 因疫情解封致營收成長 | ||
| 2023/10 | 0.88 | 12.01 | 89.69 | 7.65 | 79.92 | 2.5 | N/A | 因疫情解封致營收成長 | ||
| 2023/9 | 0.79 | -5.53 | 69.75 | 6.77 | 78.72 | 2.43 | N/A | 因疫情趨緩致營收成長 | ||
| 2023/8 | 0.83 | 3.36 | 71.95 | 5.98 | 79.98 | 2.42 | N/A | 因疫情趨緩致營收成長 | ||
| 2023/7 | 0.81 | 2.91 | 86.26 | 5.15 | 81.35 | 2.37 | N/A | 因疫情趨緩致營收成長 | ||
| 2023/6 | 0.78 | -0.32 | 139.22 | 4.34 | 80.46 | 2.38 | N/A | 因疫情趨緩致營收成長 | ||
| 2023/5 | 0.79 | -3.46 | 109.4 | 3.56 | 71.21 | 2.35 | N/A | 因疫情解封致營收成長 | ||
| 2023/4 | 0.81 | 8.49 | 92.36 | 2.77 | 62.81 | 2.19 | N/A | 因疫情解封致營收成長 | ||
| 2023/3 | 0.75 | 19.54 | 90.17 | 1.96 | 53.05 | 1.96 | N/A | 因疫情解封致營收成長 | ||
| 2023/2 | 0.63 | 7.49 | 47.62 | 1.21 | 36.55 | 1.94 | N/A | - | ||
| 2023/1 | 0.58 | -19.65 | 26.35 | 0.58 | 26.35 | 1.79 | N/A | - | ||
| 2022/12 | 0.73 | 49.95 | 19.2 | 5.46 | 39.47 | 1.68 | N/A | - | ||
| 2022/11 | 0.48 | 4.27 | 30.54 | 4.74 | 43.21 | 1.41 | N/A | - | ||
| 2022/10 | 0.46 | 0.23 | 31.76 | 4.25 | 44.81 | 1.41 | N/A | - | ||
| 2022/9 | 0.46 | -4.31 | 45.07 | 3.79 | 46.59 | 1.38 | N/A | - | ||
| 2022/8 | 0.48 | 11.97 | 54.54 | 3.32 | 46.8 | 1.24 | N/A | 因疫情趨緩致營收成長 | ||
| 2022/7 | 0.43 | 32.17 | 105.96 | 2.84 | 45.56 | 1.14 | N/A | 因疫情趨緩致營收成長 | ||
| 2022/6 | 0.33 | -12.75 | 160.66 | 2.41 | 38.27 | 1.13 | N/A | 因疫情趨緩致營收成長 | ||
| 2022/5 | 0.38 | -11.32 | 50.44 | 2.08 | 28.76 | 1.19 | N/A | 因疫情趨緩致營收成長 | ||
| 2022/4 | 0.42 | 7.26 | 15.62 | 1.7 | 24.8 | 1.24 | N/A | - | ||
| 2022/3 | 0.39 | -7.2 | 27.72 | 1.28 | 28.15 | 1.28 | N/A | - | ||
| 2022/2 | 0.42 | -7.99 | 30.48 | 0.89 | 28.35 | 1.5 | N/A | - | ||
| 2022/1 | 0.46 | -24.2 | 26.45 | 0.46 | 26.45 | 1.44 | N/A | - | ||
| 2021/12 | 0.61 | 64.21 | 41.89 | 3.92 | -11.23 | 1.33 | N/A | - | ||
| 2021/11 | 0.37 | 5.25 | 4.45 | 3.31 | -16.96 | 1.04 | N/A | - | ||
| 2021/10 | 0.35 | 10.36 | -6.93 | 2.94 | -19.06 | 0.99 | N/A | - | ||
| 2021/9 | 0.32 | 1.93 | -10.05 | 2.58 | -20.47 | 0.84 | N/A | - | ||
| 2021/8 | 0.31 | 49.22 | -17.32 | 2.26 | -21.75 | 0.0 | N/A | - | ||
| 2021/7 | 0.21 | 67.28 | -36.85 | 1.95 | -22.42 | 0.0 | N/A | - |